Reportedly, JNK activation is one of the crucial pathways for apoptosis induction by the leading anti-MM agents such as proteasome inhibitors or immunomodulatory drugs (IMiDs), or various new candidate agents for MM [21]–[24]. This evidence concerns the gene MAPK8 and Miyoshi myopathy.